These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11004016)

  • 1. Synergy of L-arginine and growth hormone (GH)-releasing peptide-2 on GH release: influence of gender.
    Wideman L; Weltman JY; Patrie JT; Bowers CY; Shah N; Story S; Weltman A; Veldhuis JD
    Am J Physiol Regul Integr Comp Physiol; 2000 Oct; 279(4):R1455-66. PubMed ID: 11004016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise.
    Wideman L; Weltman JY; Patrie JT; Bowers CY; Shah N; Story S; Veldhuis JD; Weltman A
    Am J Physiol Regul Integr Comp Physiol; 2000 Oct; 279(4):R1467-77. PubMed ID: 11004017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
    Anderson SM; Shah N; Evans WS; Patrie JT; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):551-60. PubMed ID: 11158008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.
    Veldhuis JD; Evans WS; Bowers CY
    J Clin Endocrinol Metab; 2002 Feb; 87(2):859-66. PubMed ID: 11836333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females--a general clinical research center-based study.
    Veldhuis JD; Roemmich JN; Rogol AD
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2385-94. PubMed ID: 10902783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.
    Anderson SM; Wideman L; Patrie JT; Weltman A; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5904-11. PubMed ID: 11739462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrasting negative-feedback control of endogenously driven and exercise-stimulated pulsatile growth hormone secretion in women and men.
    Veldhuis JD; Patrie J; Wideman L; Patterson M; Weltman JY; Weltman A
    J Clin Endocrinol Metab; 2004 Feb; 89(2):840-6. PubMed ID: 14764803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
    Friend K; Iranmanesh A; Login IS; Veldhuis JD
    Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of gender and systemic estradiol and testosterone concentrations to maximal secretagogue drive of burst-like growth hormone secretion in healthy middle-aged and older adults.
    Veldhuis JD; Patrie JT; Brill KT; Weltman JY; Mueller EE; Bowers CY; Weltman A
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6291-6. PubMed ID: 15579792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time mode of growth hormone (GH) entry into the bloodstream and steady-state plasma GH concentrations, rather than sex, estradiol, or menstrual cycle stage, primarily determine the GH elimination rate in healthy young women and men.
    Shah N; Aloi J; Evans WS; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2862-9. PubMed ID: 10443692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testosterone supplementation in healthy older men drives GH and IGF-I secretion without potentiating peptidyl secretagogue efficacy.
    Veldhuis JD; Keenan DM; Mielke K; Miles JM; Bowers CY
    Eur J Endocrinol; 2005 Oct; 153(4):577-86. PubMed ID: 16189179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ghrelin potentiates growth hormone secretion driven by putative somatostatin withdrawal and resists inhibition by human corticotropin-releasing hormone.
    Veldhuis JD; Iranmanesh A; Mielke K; Miles JM; Carpenter PC; Bowers CY
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2441-6. PubMed ID: 16537682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys.
    Richmond E; Rogol AD; Basdemir D; Veldhuis OL; Clarke W; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic somatostatin analog (octreotide) suppresses daytime growth hormone secretion equivalently in young and older men: preserved pituitary responsiveness to somatostatin's inhibition in aging.
    Mulligan T; Jaen-Vinuales A; Godschalk M; Iranmanesh A; Veldhuis JD
    J Am Geriatr Soc; 1999 Dec; 47(12):1422-4. PubMed ID: 10591235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol supplementation enhances submaximal feed-forward drive of growth hormone (GH) secretion by recombinant human GH-releasing hormone-1,44-amide in a putatively somatostatin-withdrawn milieu.
    Veldhuis JD; Evans WS; Bowers CY
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5484-9. PubMed ID: 14602794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.